CL2016002870A1 - Derivados bicíclicos y composición farmacéutica que incluye los mismos - Google Patents

Derivados bicíclicos y composición farmacéutica que incluye los mismos

Info

Publication number
CL2016002870A1
CL2016002870A1 CL2016002870A CL2016002870A CL2016002870A1 CL 2016002870 A1 CL2016002870 A1 CL 2016002870A1 CL 2016002870 A CL2016002870 A CL 2016002870A CL 2016002870 A CL2016002870 A CL 2016002870A CL 2016002870 A1 CL2016002870 A1 CL 2016002870A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
sglt
present
bicyclic derivatives
kidneys
Prior art date
Application number
CL2016002870A
Other languages
English (en)
Inventor
Ji Sook Kim
Won Jeoung Kim
Wook Jang
Ji Young Song
Moon Sub Lee
Nam Du Kim
Kwee Hyun Suh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020140057428A external-priority patent/KR20150130177A/ko
Priority claimed from KR1020140081343A external-priority patent/KR20160002257A/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2016002870A1 publication Critical patent/CL2016002870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La presente invención se refiere a un nuevo derivado bicíclico que tiene una actividad inhibidora frente a transportadores ligados de sodio-glucosa (SGLT) presentes en los intestinos y los riñones, o una sal, isómero, hidrato o solvato farmacéuticamente aceptables de los mismos, y una composición farmacéutica que incluye el mismo como un ingrediente activo, que inhiben eficazmente la actividad de SGLT, y por lo tanto puede ser usado como un agente terapéutico para el tratamiento de enfermedades causadas p</p>
CL2016002870A 2014-05-13 2016-11-10 Derivados bicíclicos y composición farmacéutica que incluye los mismos CL2016002870A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140057428A KR20150130177A (ko) 2014-05-13 2014-05-13 Sglt 저해제로서 2,3-다이하이드로벤조퓨란 유도체 및 이를 포함하는 약학적 조성물
KR1020140081343A KR20160002257A (ko) 2014-06-30 2014-06-30 Sglt 저해제로서 인단 유도체 및 이를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
CL2016002870A1 true CL2016002870A1 (es) 2017-08-18

Family

ID=54480186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002870A CL2016002870A1 (es) 2014-05-13 2016-11-10 Derivados bicíclicos y composición farmacéutica que incluye los mismos

Country Status (15)

Country Link
US (1) US9828366B2 (es)
EP (1) EP3143017A4 (es)
JP (1) JP2017515846A (es)
CN (1) CN105085454A (es)
AU (1) AU2015260082A1 (es)
CA (1) CA2948130A1 (es)
CL (1) CL2016002870A1 (es)
IL (1) IL248490A0 (es)
MX (1) MX2016013760A (es)
PH (1) PH12016502226A1 (es)
RU (1) RU2016144355A (es)
SG (1) SG11201608660TA (es)
TW (1) TW201623321A (es)
WO (1) WO2015174695A1 (es)
ZA (1) ZA201607353B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3404033T3 (da) * 2016-01-04 2020-11-02 Jeil Pharmaceutical Co Ltd C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette
US20250129055A1 (en) * 2020-11-19 2025-04-24 Beijing Increase Innovative Drug Co., Ltd. Glucoside derivative, and preparation method therefor and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
WO2002038559A1 (en) * 2000-11-10 2002-05-16 Novo Nordisk A/S 1,3-diazaheterocyclic compounds and their use as oral hypoglycaemic agents
WO2003087093A1 (en) 2002-04-08 2003-10-23 Council Of Scientific And Industrial Research Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
ES2363941T3 (es) * 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
ES2531660T3 (es) * 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
WO2006082245A1 (en) 2005-02-07 2006-08-10 Novo Nordisk A/S Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand
WO2010074219A1 (ja) * 2008-12-26 2010-07-01 アステラス製薬株式会社 ベンゾチオフェン化合物

Also Published As

Publication number Publication date
JP2017515846A (ja) 2017-06-15
CA2948130A1 (en) 2015-11-19
US9828366B2 (en) 2017-11-28
CN105085454A (zh) 2015-11-25
TW201623321A (zh) 2016-07-01
AU2015260082A1 (en) 2016-11-03
US20170066750A1 (en) 2017-03-09
SG11201608660TA (en) 2016-11-29
WO2015174695A1 (en) 2015-11-19
MX2016013760A (es) 2017-03-09
EP3143017A1 (en) 2017-03-22
RU2016144355A (ru) 2018-06-19
IL248490A0 (en) 2016-12-29
ZA201607353B (en) 2018-05-30
EP3143017A4 (en) 2017-12-13
PH12016502226A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX377845B (es) Inhibidores de calicreína plasmática humana.
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
MX2021014049A (es) Compuestos espiro triciclicos.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX2015012537A (es) Derivados de dihidropiridazin-3,5-diona.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY36124A (es) Derivados de carboxamida
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
UY36123A (es) Derivados de carboxamida
PE20170430A1 (es) Arilhidrazidas que contienen una fraccion de 2-piridona como agentes antibacterianos selectivos
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos
MX2018003381A (es) Profilactico o agente terapeutico para queratitis fungica.
CL2018000085A1 (es) Carbonitrilos de heteroarilo para el tratamiento de enfermedades
BR112017003880A2 (pt) derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak
BR112016016674A2 (pt) Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla
CU20160170A7 (es) Derivados de carboxamida